Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Institute of Cancer Research · Breast Cancer Research Foundation · +9 more institutions
Abstract
Fifty patients were treated: 48 had germline BRCA1/2 mutations; one had a BRCA2 germline sequence change of unknown significance, and another had a strong family history of BRCA1/2-associated cancers who declined mutation testing. Of the 50 patients, 13 had platinum-sensitive disease, 24 had platinum-resistant disease, and 13 had platinum-refractory disease (according to platinum-free interval). Twenty (40%; 95% CI, 26% to 55%) achieved Response Evaluation Criteria in Solid Tumors (RECIST) complete or partial responses and/or tumor marker (CA125) responses, and three (6.0%) maintained RECIST disease stabilization for more than 4 months, giving an overall clinical benefit rate of 46% (95% CI, 32% to 61%). Median response duration was 28 weeks. There was a significant association between the clinical benefit rate and platinum-free interval across the platinum-sensitive, resistant, and refractory subgroups (69%, 45%, and 23%, respectively). Post hoc analyses indicated associations between platinum sensitivity and extent of olaparib response (radiologic change, P = .001; CA125 change, P = .002).
Olaparib has antitumor activity in BRCA1/2 mutation ovarian cancer, which is associated with platinum sensitivity.
Citation impact
- FWCI
- 43.81
- Percentile
- 100%
- References
- 28
Authors
18- PCPeter C.C. FongCorresponding
Institute of Cancer Research, Breast Cancer Research Foundation, Breast Cancer Now
- TATimothy A. Yap
National Health Service, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Utrecht University, Breast Cancer Research Foundation, Breast Cancer Now, Cancer Research UK, Cancer Institute (WIA), Breakthrough, Universitair Ziekenhuis Brussel, International Hereditary Cancer Center
- DSDavid S. Boss
National Health Service, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Utrecht University, Breast Cancer Research Foundation, Breast Cancer Now, Cancer Research UK, Cancer Institute (WIA), Breakthrough, Universitair Ziekenhuis Brussel, International Hereditary Cancer Center
- CPCraig P. Carden
National Health Service, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Utrecht University, Breast Cancer Research Foundation, Breast Cancer Now, Cancer Research UK, Cancer Institute (WIA), Breakthrough, Universitair Ziekenhuis Brussel, International Hereditary Cancer Center
- MMMarja Mergui‐Roelvink
National Health Service, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Utrecht University, Breast Cancer Research Foundation, Breast Cancer Now, Cancer Research UK, Cancer Institute (WIA), Breakthrough, Universitair Ziekenhuis Brussel, International Hereditary Cancer Center
Topics & keywords
- Olaparib
- Medicine
- Ovarian cancer
- BRCA mutation
- Internal medicine
- PARP inhibitor
- Oncology
- Chemotherapy
- Good health and well-being